Home > Insider Trading > Filing (0001209191-19-021017)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1690585	Magenta Therapeutics Inc.	MGTA	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1628098	Atlas Venture Fund X, L.p.	400 Technology Square, 10Th Floor Cambridge MA 02139	No	No	Yes	No
1742765	Atlas Venture Associates X, Llc	400 Technology Square, 10Th Floor Cambridge MA 02139	No	No	Yes	No
1742766	Atlas Venture Associates X, L.p.	400 Technology Square, 10Th Floor Cambridge MA 02139	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-03-20	726,500	$0.00	4,117,125	No	4	J	Direct
Common Stock	Acquisiton	2019-03-20	14,245	$0.00	14,245	No	4	J	Indirect	See Footnote
Common Stock	Disposition	2019-03-20	14,245	$17.86	0	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	J	Direct
No	4	J	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund X, L.P. ("AVF X") to its general partner and limited partners without additional consideration.
The shares are held directly by AVF X. The general partner of AVF X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by AVF X, except to the extent of its pecuniary interest therein, if any.
Represents the shares received by AVA X LP in connection with the pro rata distribution described in footnote 1 by AVF X.
The shares are held directly by AVA X LP. AVA X LLC is the general partner of AVA X LP. AVA X LLC disclaims Section 16 beneficial ownership of the securities held by AVA X LP, except to the extent of its pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold by AVA X LP in multiple transactions at prices ranging from $17.75 to $18.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.